Overview
Refractory migraine with aura is a debilitating neurological condition characterized by recurrent headaches accompanied by neurological symptoms (aura) that persist despite adherence to multiple prophylactic treatments. This condition significantly impacts quality of life and often requires specialized management due to its resistance to conventional therapies. Affecting approximately 1-2% of the population, refractory migraine disproportionately burdens individuals with frequent and severe attacks, necessitating comprehensive and multidisciplinary approaches in day-to-day clinical practice to optimize outcomes and reduce suffering 35.Pathophysiology
The pathophysiology of refractory migraine with aura involves complex interactions at molecular, cellular, and neural network levels. Cortical spreading depression (CSD), a wave of neuronal and glial depolarization, is a critical mechanism underlying aura symptoms 1. Dysfunctions in voltage-dependent sodium channels and glutamate receptors, particularly NMDA receptors, contribute to the generation of CSD episodes 1. Although calcitonin gene-related peptide (CGRP) has been implicated in migraine pathophysiology, its direct role in CSD propagation remains less clear, suggesting a multifaceted involvement of neuropeptides and ion channels 1. Additionally, the interplay between central sensitization and peripheral triggers, such as CGRP release from trigeminal nerves, amplifies pain signaling and contributes to the chronicity and refractoriness of migraine attacks 3.Epidemiology
Chronic migraine, including its refractory form, affects approximately 1.3% to 5.1% of the global population, with a higher prevalence among women compared to men 3. The condition typically emerges in adulthood, with peak incidence around the third to fourth decade of life, though it can occur at any age 5. Risk factors include a history of episodic migraine, medication overuse headache (MOH), and comorbid conditions such as obesity, obstructive sleep apnea, and temporomandibular disorders 4. Trends indicate an increasing prevalence, possibly linked to lifestyle factors and increased awareness of headache disorders 3.Clinical Presentation
Refractory migraine with aura presents with recurrent headaches often lasting more than 4 hours, frequently accompanied by transient neurological symptoms such as visual disturbances (aura). Typical aura symptoms include visual phenomena (e.g., scintillating scotomas), sensory disturbances, and speech difficulties. Atypical presentations may involve more severe neurological deficits or prolonged aura duration, raising concerns for secondary causes 5. Red-flag features include sudden onset of new neurological symptoms, progressive neurological deficits, or signs of raised intracranial pressure, necessitating urgent neurological evaluation to rule out other pathologies 5.Diagnosis
Diagnosing refractory migraine with aura involves a thorough clinical history and exclusion of other causes. Key diagnostic criteria include:Management
First-Line Management
Second-Line Management
Refractory / Specialist Escalation
Contraindications
Complications
Prognosis & Follow-up
The prognosis for refractory migraine with aura varies widely, influenced by factors such as adherence to treatment, presence of comorbid conditions, and effectiveness of interventions. Prognostic indicators include early diagnosis and aggressive management of MOH, response to preventive medications, and engagement in behavioral therapies. Recommended follow-up intervals typically involve monthly visits initially, tapering to every 3-6 months if stable, with regular reassessment of headache frequency, medication efficacy, and side effects 5.Special Populations
Key Recommendations
References
1 Tozzi A, de Iure A, Di Filippo M, Costa C, Caproni S, Pisani A et al.. Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proceedings of the National Academy of Sciences of the United States of America 2012. link 2 Andrade SM, de Brito Aranha REL, de Oliveira EA, de Mendonça CTPL, Martins WKN, Alves NT et al.. Transcranial direct current stimulation over the primary motor vs prefrontal cortex in refractory chronic migraine: A pilot randomized controlled trial. Journal of the neurological sciences 2017. link 3 Lionetto L, Negro A, Palmisani S, Gentile G, Del Fiore MR, Mercieri M et al.. Emerging treatment for chronic migraine and refractory chronic migraine. Expert opinion on emerging drugs 2012. link 4 Lovell BV, Marmura MJ. New therapeutic developments in chronic migraine. Current opinion in neurology 2010. link 5 Lake AE, Saper JR, Hamel RL. Comprehensive inpatient treatment of refractory chronic daily headache. Headache 2009. link 6 Kaube H, Goadsby PJ. Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat. European neurology 1994. link